{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:48Z","timestamp":1790957628303,"version":"4.1.0"},"reference-count":172,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[1998,4,14]]},"abstract":"<jats:p>\n                    <jats:italic>Abstract<\/jats:italic>\n                    \u2014ACE inhibitors have achieved widespread usage in the treatment of cardiovascular and renal disease. ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive, and hypertrophic properties of angiotensin II (Ang II) and the vasodilatory and natriuretic properties of bradykinin and alter the metabolism of a number of other vasoactive substances. ACE inhibitors differ in the chemical structure of their active moieties, in potency, in bioavailability, in plasma half-life, in route of elimination, in their distribution and affinity for tissue-bound ACE, and in whether they are administered as prodrugs. Thus, the side effects of ACE inhibitors can be divided into those that are class specific and those that relate to specific agents. ACE inhibitors decrease systemic vascular resistance without increasing heart rate and promote natriuresis. They have proved effective in the treatment of hypertension, they decrease mortality in congestive heart failure and left ventricular dysfunction after myocardial infarction, and they delay the progression of diabetic nephropathy. Ongoing studies will elucidate the effect of ACE inhibitors on cardiovascular mortality in essential hypertension, the role of ACE inhibitors in patients without ventricular dysfunction after myocardial infarction, and the role of ACE inhibitors compared with newly available angiotensin AT\n                    <jats:sub>1<\/jats:sub>\n                    receptor antagonists.\n                  <\/jats:p>","DOI":"10.1161\/01.cir.97.14.1411","type":"journal-article","created":{"date-parts":[[2012,6,11]],"date-time":"2012-06-11T20:41:02Z","timestamp":1339447262000},"page":"1411-1420","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":608,"title":["Angiotensin-Converting Enzyme Inhibitors"],"prefix":"10.1161","volume":"97","author":[{"given":"Nancy J.","family":"Brown","sequence":"first","affiliation":[{"name":"From the Departments of Medicine and Pharmacology, Vanderbilt University Medical Center (N.J.B., D.E.V.), and the Veterans Administration Medical Center (D.E.V.), Nashville, Tenn."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Vaughan","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine and Pharmacology, Vanderbilt University Medical Center (N.J.B., D.E.V.), and the Veterans Administration Medical Center (D.E.V.), Nashville, Tenn."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","unstructured":"Skidgel RA Erdos E. Biochemistry of angiotensin I-converting enzyme. In: Robertson JIS Nicholls MG eds. The Renin-Angiotensin System. New York NY: Raven Press Ltd; 1993:10.1\u201310.10."},{"key":"e_1_3_2_2_2","unstructured":"Sealey JE Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH Brenner BM eds. Hypertension: Pathophysiology Diagnosis and Management. New York NY: Raven Press Ltd; 1990:1287\u20131317."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.24.1.37"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cardiovasc Pharmacol. 1993;22(suppl):S1\u2013S9.","DOI":"10.1097\/00005344-199322005-00002"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6604942"},{"key":"e_1_3_2_6_2","first-page":"1760","volume":"36","year":"1977","unstructured":"Erdos EG. The angiotensin I converting enzyme. Fed Proc. 1977;36:1760\u20131765.","journal-title":"Fed Proc"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1961.tb02267.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198412000-00002"},{"key":"e_1_3_2_9_2","first-page":"338","volume":"60","year":"1961","unstructured":"Biron P, Koiw E, Nowaczynski W. The effects of intravenous infusions of valine-5 angiotensin II and other pressor agents on urinary electrolytes and corticoids including aldosterone. J Clin Invest. 1961;60:338\u2013347.","journal-title":"J Clin Invest"},{"key":"e_1_3_2_10_2","first-page":"251","volume":"74","year":"1977","unstructured":"Padfield PL, Morton JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. J Clin Endocrinol. 1977;74:251\u2013259.","journal-title":"J Clin Endocrinol"},{"key":"e_1_3_2_11_2","first-page":"7","volume":"137","year":"1990","unstructured":"Bell L, Madri J. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990;137:7\u201312.","journal-title":"Am J Pathol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.68.2.1991349"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116454"},{"key":"e_1_3_2_14_2","first-page":"15","volume":"157","year":"1996","unstructured":"Dostal DE, Booz GW, Baker KM. Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Mol Cell Biochem. 1996;157:15\u201321.","journal-title":"Mol Cell Biochem"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0955-2235(94)90004-3"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0031-6997(25)00446-6","volume":"45","year":"1993","unstructured":"Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharm Rev. 1993;45:205\u2013251.","journal-title":"Pharm Rev"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.06.040188.000405"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.13.6.658"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106972"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06836-X","volume":"32","year":"1980","unstructured":"Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1\u201346.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0026-895X(25)14945-6","volume":"25","year":"1984","unstructured":"Cascieri MA, Bull HG, Mumford RA, Patchett AA, Thornberry NA, Liang T. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422. Mol Pharmacol. 1984;25:287\u2013293.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_22_2","first-page":"13","volume":"10","year":"1987","unstructured":"Zusman RM. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis. 1987;10:13\u201323.","journal-title":"Am J Kidney Dis"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1994.tb36771.x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1989.tb01563.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3565(25)32897-1","volume":"220","year":"1982","unstructured":"Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther. 1982;220:63\u201369.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.11.3.230"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.92"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-90-1-19"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197805042981803"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-120-30547"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Ferrario CM Brosnihan KB Diz DI Jaiswal N Khosla MC Milsted A Tallant EA. Angiotensin-(1\u20137): a new hormone of the angiotensin system. Hypertension. 1991;18(suppl III):III-126\u2013III-133.","DOI":"10.1161\/01.HYP.18.5_Suppl.III126"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198406000-00010"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.66.4.2156635"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)45712-2"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.16.5.564"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198211000-00014"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(82)90390-3"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199015061-00010"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0022-3565(25)21179-X","volume":"279","year":"1996","unstructured":"Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of ACE inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther. 1996;279:703\u2013712.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109788"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Tanaka S Shimamoto K Ando T Nakahashi Y Ura N Hosoda S Ishida H Yamaji I Yokoyama T Masuda A Iimura O. Role of renin-angiotensin and kallikrein-kinin systems on the mechanism of the hypotensive effects of converting enzyme inhibitor alacepril. Clin Exp Hypertens. 1987;A9:605\u2013609.","DOI":"10.3109\/10641968709164231"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)90361-4"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)91552-6"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198311000-00015"},{"key":"e_1_3_2_45_2","first-page":"40","volume":"44","year":"1986","unstructured":"Stanek B, Silberbauer K. Acute and chronic effects of captopril on bicyclo-PGEm, the stable bicyclic end product of prostaglandin E2 in essential hypertension. Nephron. 1986;44:40\u201345.","journal-title":"Nephron"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0262-1746(83)90014-8"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs063265s"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.184"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(82)90376-9"},{"key":"e_1_3_2_50_2","first-page":"328","volume":"36","year":"1981","unstructured":"Ogihara T, Maruyama A, Hata T, Mikami H, Nakamaru M, Naka T, Ohde H, Kumahara Y. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. Clin Pharmacol Ther. 1981;36:328\u2013335.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","unstructured":"Omata K Abe K Tsunoda K Yasujima M Chiba S Sata M Kudo K Yoshinaga K. Role of endogenous angiotensin II and prostaglandins in the antihypertensive mechanism of angiotensin converting enzyme inhibitor in hypertension. Clin Exp Hypertens. 1987;A9:569\u2013574.","DOI":"10.3109\/10641968709164225"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb12248.x"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1991.tb12249.x"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb17052.x"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb09054.x"},{"key":"e_1_3_2_56_2","first-page":"497","volume":"30","year":"1997","unstructured":"Gainer JV, Morrow JD, King DJ, Brown NJ. HOE 140 attenuates the hypotensive effect of captopril in humans. Hypertension. 1997;30:497. Abstract.","journal-title":"Hypertension"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.95.5.1115"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198402000-00009"},{"key":"e_1_3_2_59_2","doi-asserted-by":"crossref","unstructured":"Ibsen H Egan B Osterzeil K Vander A Julius S. Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans. Hypertension. 1983;5(suppl I):I-184\u2013I-189.","DOI":"10.1161\/01.HYP.5.2_Pt_2.I184"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(84)90692-1"},{"key":"e_1_3_2_61_2","first-page":"S45","volume":"7","year":"1985","unstructured":"Simon AC, Levenson JA, Bouthier J, Maarek B, Safar ME. Effects of acute and chronic angiotensin enzyme inhibition on large arteries in human hypertension. J Cardiovasc Pharmacol. 1985;7:S45\u2013S51.","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_3_2_62_2","first-page":"453","volume":"55","year":"1978","unstructured":"Cody RJ, Tarazi RC, Bravo EL, Fouad FM. Haemodynamics of orally-active converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci Mol Med. 1978;55:453\u2013459.","journal-title":"Clin Sci Mol Med"},{"key":"e_1_3_2_63_2","unstructured":"Fouad FM Tarazi RC Bravo EL. Cardiac and haemodynamic effects of enalapril. J Hypertens. 1983;1(suppl 1):135\u2013142."},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(80)90074-0"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.2.4.576"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(82)90354-X"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0570421"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1981.126"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.1.3.274"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198201283060405"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198631030-00002"},{"key":"e_1_3_2_72_2","first-page":"S36","volume":"3","year":"1987","unstructured":"Pool JL, Gennari J, Goldstein R, Kochar MS, Lewin AJ, Maxwell MH, McChesney JA, Mehta J, Nash DT, Nelson EB, Rastogi S, Rofman B, Weinberger M. Controlled multicenter study of antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol. 1987;3:S36\u2013S42.","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198007000-00001"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198405000-00010"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(82)90278-2"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.2.2.236"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1989.tb04149.x"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb02064.x"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304013281303"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90812-4"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(67)90193-3"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(72)90067-8"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.26.1.124"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(87)80067-X"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05063.x"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb02793.x"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(89)90764-3"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440420033005"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/7.1.82"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.110.4.1361"},{"key":"e_1_3_2_91_2","doi-asserted-by":"crossref","unstructured":"Suter PM Vetter W. Metabolic effects of antihypertensive drugs. J Hypertens. 1995;13(suppl):S11\u2013S17.","DOI":"10.1097\/00004872-199512002-00003"},{"key":"e_1_3_2_92_2","first-page":"1044","volume":"53","year":"1994","unstructured":"Nakashima Y, Fouad FM, Tarazi RC. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol. 1994;53:1044\u20131049.","journal-title":"Am J Cardiol"},{"key":"e_1_3_2_93_2","first-page":"789","volume":"37","year":"1992","unstructured":"Gaudio C, Tanzilli G, Collatina S, Pagnotta P, Paknejad K, Campa PP. Evaluation of regression of left ventricular hypertrophy in hypertensive patients treated with captopril as assessed by magnetic resonance imaging. Cardiologia. 1992;37:789\u2013791.","journal-title":"Cardiologia"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250502"},{"key":"e_1_3_2_97_2","first-page":"821","volume":"342","year":"1993","unstructured":"AIRE Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821\u2013828.","journal-title":"Lancet"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332503"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.58.5.699245"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.58.5.699246"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)91897-X"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197907193010301"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(79)90237-6"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006193022501"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.62.1.6247102"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92593-3"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90004-0"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(82)90048-5"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92889-N"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01187-2"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/28.2.159"},{"key":"e_1_3_2_114_2","unstructured":"Dahlof B. Effect of angiotensin II a blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens. 1995;9(suppl):S37\u2013S44."},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530430051039"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.57.1.3891127"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198807143190204"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271002"},{"key":"e_1_3_2_119_2","unstructured":"ISIS Collaborative Group. ISIS-4: randomised study of oral captopril in over 50 000 patients with suspected acute myocardial infarction. Circulation. 1993;88(suppl I):I-394."},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501123320203"},{"key":"e_1_3_2_121_2","first-page":"1115","volume":"343","year":"1994","unstructured":"Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115\u20131122.","journal-title":"Lancet"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.46.1.455"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00050991"},{"key":"e_1_3_2_124_2","doi-asserted-by":"crossref","unstructured":"Hayek T Keidar S Mei-Yi Oiknine J Breslow J. Effect of angiotensin converting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis progression in apo E deficient mice. Circulation. 1995;92(suppl I):I-625.","DOI":"10.1016\/0021-9150(95)96529-2"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.15.3.327"},{"key":"e_1_3_2_126_2","doi-asserted-by":"crossref","unstructured":"Aberg G Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl):S65\u2013S72.","DOI":"10.1097\/00005344-199000155-00010"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.94.3.258"},{"key":"e_1_3_2_128_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(25)06820-6","volume":"47","year":"1995","unstructured":"Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25\u201349.","journal-title":"Pharmacol Rev"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117809"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.87.6.8504511"},{"key":"e_1_3_2_131_2","first-page":"285","volume":"38","year":"1992","unstructured":"Emeis JJ, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions. 1992;38:285\u2013291.","journal-title":"Agents Actions"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656000"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)00526-7"},{"key":"e_1_3_2_134_2","first-page":"127","volume":"12","year":"1996","unstructured":"The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Am J Cardiol. 1996;12:127\u2013137.","journal-title":"Am J Cardiol"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90882-9"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112528"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1990.314"},{"key":"e_1_3_2_138_2","first-page":"S51","volume":"12","year":"1994","unstructured":"Ruiz-Ortega M, Gomez-Garre D, Alcazar R, Palacios I, Bustos C, Gonzalez S, Plaza JJ, Gonzalez E, Egido J. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens. 1994;12:S51\u2013S58.","journal-title":"J Hypertens"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04748.x"},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440030080010"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604113341502"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116732"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114844"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118270"},{"key":"e_1_3_2_145_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7057.591"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6368.832"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1980.03310220049028"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90415-6"},{"key":"e_1_3_2_149_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1984.00350220091020"},{"key":"e_1_3_2_150_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198302173080706"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(87)80016-1"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6420.844"},{"key":"e_1_3_2_153_2","first-page":"F897","volume":"246","year":"1984","unstructured":"Kastner PR, Hall JE, Guyton AC. Control of glomerular filtration rate: role of intrarenally formed angiotensin II. Am J Physiol. 1984;246:F897\u2013F906.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.279"},{"key":"e_1_3_2_155_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-3-234"},{"key":"e_1_3_2_156_2","first-page":"141","volume":"40","year":"1995","unstructured":"Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol. 1995;40:141\u2013144.","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)00231-E"},{"key":"e_1_3_2_158_2","first-page":"372","volume":"339","year":"1992","unstructured":"Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female sex as an important determinant of lisinopril-induced cough. Lancet. 1992;339:372. Letter.","journal-title":"Lancet"},{"key":"e_1_3_2_159_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410070095035"},{"key":"e_1_3_2_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90161-7"},{"key":"e_1_3_2_161_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02254221"},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V391575"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259832"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1983.00350040049004"},{"key":"e_1_3_2_165_2","first-page":"660","volume":"3","year":"1982","unstructured":"Erslev AJ, Alexander JC, Caro J, Boyd RL. Hematologic side effects of captopril and associated risk factors. Cardiovasc Rev Rep. 1982;3:660\u2013671.","journal-title":"Cardiovasc Rev Rep"},{"key":"e_1_3_2_166_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03088.x"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6475.1111"},{"key":"e_1_3_2_168_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03015.x"},{"key":"e_1_3_2_169_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(84)80055-8"},{"key":"e_1_3_2_170_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198702000-00017"},{"key":"e_1_3_2_171_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.3.2.168"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.44.422"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.97.14.1411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T17:30:39Z","timestamp":1743355839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.97.14.1411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4,14]]},"references-count":172,"journal-issue":{"issue":"14","published-print":{"date-parts":[[1998,4,14]]}},"alternative-id":["10.1161\/01.CIR.97.14.1411"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.97.14.1411","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,4,14]]},"assertion":[{"value":"1997-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-04-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}